Monsalve 2017 Abstract MITOEAGLE Barcelona: Difference between revisions
(Created page with "{{Abstract |title=left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE |info=MITOEAGLE |authors= |year=...") Β |
No edit summary |
||
Line 1: | Line 1: | ||
{{Abstract | {{Abstract | ||
|title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | |title=[[File:MITOEAGLE-representation.jpg|left|60px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | ||
Mitochondrial biogenesis in PMBC: potential biomarkers | |||
|info=[[MITOEAGLE]] | |info=[[MITOEAGLE]] | ||
|authors= | |authors=Fabregat-Andres O, Ridocci-Soriano F,Β Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M | ||
|year=2017 | |year=2017 | ||
|event=MITOEAGLE Barcelona 2017 | |event=MITOEAGLE Barcelona 2017 | ||
|abstract=[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | |abstract=[[Image:MITOEAGLE-logo.jpg|left|100px|link=http://www.mitoglobal.org/index.php/MITOEAGLE|COST Action MITOEAGLE]] | ||
Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI. | |||
We prospectively studied 31 patients with a first anterior STEMI successfully reperfused. We analyzed PGC-1a mRNA in blood samples on admission and 72 h later, and tested its correlation with the extent of initial myocardial damage and cardiac volume and function at 6 months. Myocardial edema and necrosis were assessed during the first week by cardiac magnetic resonance (CMR). A second CMR examination was performed at 6 months to evaluate scar burden and AVR, defined as an increase over 10% in left ventricular end-diastolic volume (LVEDV). | |||
PGC-1a induction is associated with larger edemas and higher risk of AVR. Patients with high basal PGC-1a levels have larger areas of initial salvaged myocardium (SM) and SM at 6 months. In the absence of microvascular obstruction (MVO) and with high basal PGC-1a, the risk of AVR is lower than in the presence of MVO with low basal PGC-1a. | |||
Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI. | |||
}} | |||
{{Labeling | |||
|area=mt-Biogenesis;mt-density | |||
|tissues=Blood cells | |||
|additional=PMBCs, | |||
}} | }} | ||
== Affiliations == | == Affiliations == | ||
:::: ( | :::: Consorcio Hospital General Univ Valencia, Inst Investigaciones BiomΓ©dicas βAlberto Solsβ (CSIC), Madrid; Spain. |
Revision as of 10:29, 3 March 2017
Mitochondrial biogenesis in PMBC: potential biomarkers |
Link: MITOEAGLE
Fabregat-Andres O, Ridocci-Soriano F, Berenguer-Jofresa A, Corbi-Pascual M, Valle-Munoz A, Barrabes JA, Estornell-Erill J, M, Monsalve M (2017)
Event: MITOEAGLE Barcelona 2017
Peroxisome proliferator activated receptor g co-activator 1a (PGC-1a) is a master on antioxidant systems. It is induced by ischemia and reperfusion (IR) and has been shown to prevent cardiac remodeling in mice. PGC-1a can be detected in blood samples of ST-segment elevation acute myocardial infarction (STEMI) patients. This study tested the predictive value of PGC-1a for cardiac healing and adverse ventricular remodeling (AVR) after STEMI.
We prospectively studied 31 patients with a first anterior STEMI successfully reperfused. We analyzed PGC-1a mRNA in blood samples on admission and 72 h later, and tested its correlation with the extent of initial myocardial damage and cardiac volume and function at 6 months. Myocardial edema and necrosis were assessed during the first week by cardiac magnetic resonance (CMR). A second CMR examination was performed at 6 months to evaluate scar burden and AVR, defined as an increase over 10% in left ventricular end-diastolic volume (LVEDV).
PGC-1a induction is associated with larger edemas and higher risk of AVR. Patients with high basal PGC-1a levels have larger areas of initial salvaged myocardium (SM) and SM at 6 months. In the absence of microvascular obstruction (MVO) and with high basal PGC-1a, the risk of AVR is lower than in the presence of MVO with low basal PGC-1a.
Baseline expression and lack of induction of PGC-1a are associated with a reduced incidence of AVR after STEMI.
Labels: MiParea: mt-Biogenesis;mt-density
Tissue;cell: Blood cells
PMBCs
Affiliations
- Consorcio Hospital General Univ Valencia, Inst Investigaciones BiomΓ©dicas βAlberto Solsβ (CSIC), Madrid; Spain.